EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System

The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. 

CLASP: resultados a 2 años del nuevo dispositivo de reparación Mitral

These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions.

The PASCAL system (Edwards) has been authorized for research protocols only in the US.  

At present, patients are being enrolled to the CLASP IID/IIF, set to test the PASCAL against the MitraClip in patients with both functional and degenerative MR. 

If it lives up to its promise, the PASCAL is likely to be authorized by the FDA for use in the clinical arena. 

There are several differences between devices: one is the ability to treat one leaflet after the other, or in tandem. 4th generation MitraClips will offer the same characteristic. 


Read also: Very Short Dual Antiplatelet Therapy after Complex PCI.


The CLASP trial included 124 patients with significant mitral valve regurgitation (≥ 3+) and functional class II to IV who made good candidates for edge-to-edge repair. 

69% of the population had functional mitral valve regurgitation and 60% were in functional class III-IV. Outcomes at 30 days and one year were presented at TCT 2020 and simultaneously published in JACC: Cardiovascular Interventions.

The new outcomes were presented at the EuroPCR; 48 patients that completed the 2 year follow up with 72% survival rate in the functional group and 94% in the degenerative group. 78% of patients presented mitral regurgitation ≤1+, which was accompanied by improved end diastolic volume and functional class. 

Original Title: Durable reduction of mitral regurgitation after 2 years: another ace up the TMVR sleeve.

Reference: Georg Goliasch et al. JACC Cardiovasc Interv. 2021 May 7;S1936-8798(21)00822-0. Online ahead of print. doi: 10.1016/j.jcin.2021.04.047. Presentado simultáneamente en el EuroPCR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....